Zotepine API is a synthetic dibenzothiepine compound belonging to the second-generation antipsychotic class. It has been investigated and used as an antipsychotic agent, particularly in relation to the treatment of schizophrenia. Zotepine interacts with multiple neurotransmitter systems, including dopamine and serotonin pathways.
Zotepine is associated with antagonistic activity at dopamine D1 and D2 receptors and several serotonin receptors, including 5-HT2A, 5-HT2C, 5-HT6 and 5-HT7. It also has activity involving serotonin and noradrenaline transporters.
Zotepine has the molecular formula C₁₈H₁₈ClNOS, a molecular weight of approximately 331.9 g/mol, and CAS Number 26615-21-4.
SDP provides sourcing and supply support for Zotepine API, subject to product availability, applicable specifications, regulatory requirements and customer requirements.
| Parameter | Details |
|---|---|
| Product Name | Zotepine |
| CAS Number | 26615-21-4 |
| Molecular Formula | C₁₈H₁₈ClNOS |
| Molecular Weight | 331.9 g/mol |
| PubChem CID | 5736 |
| ChEMBL ID | CHEMBL285802 |
| DrugBank ID | DB09225 |
| KEGG ID | D01321 |
| ChEBI ID | CHEBI:32316 |
| UNII | U29O83JAZW |
| NCI Thesaurus Code | C81096 |
| InChIKey | HDOZVRUNCMBHFH-UHFFFAOYSA-N |
The chemical identifiers and molecular properties above are reported by PubChem.
Zotepine API is the active pharmaceutical ingredient Zotepine, a neuroleptic compound that has been used as an antipsychotic in certain markets. PubChem classifies it as a dibenzothiepine and tertiary amino compound with serotonergic and alpha-adrenergic activity.
Its pharmacological profile involves interactions with dopamine and serotonin receptor systems, making it relevant to pharmaceutical research concerning psychotic disorders and antipsychotic drug development.
Zotepine exhibits activity across several neurotransmitter systems. It has antagonistic activity at dopamine D1 and D2 receptors, while also interacting with several serotonin receptors.
Its pharmacological activity also includes effects on the serotonin transporter and noradrenaline transporter, contributing to its broader neurotransmitter profile. Metabolism involves enzymes including CYP1A2 and CYP3A4.
Zotepine has been used and investigated as an antipsychotic agent in the context of schizophrenia and related psychotic disorders.
Its interaction with dopamine and serotonin receptor systems makes Zotepine relevant to research involving:
The regulatory status of Zotepine varies by jurisdiction. PubChem notes that it has not been approved by the FDA, Canada or EMA, so SDP product pages should avoid implying universal regulatory approval.
Use the actual approved Zotepine specification/CoA for numerical limits.
| Parameter | Specification |
|---|---|
| Identification | IR & HPLC compliant |
| Assay | As per approved product specification |
| Related Substances | As per approved product specification |
| Loss on Drying | As per approved product specification |
| Residue on Ignition | As per approved product specification |
| Heavy Metals / Elemental Impurities | Complies with applicable specification |
| Residual Solvents | Complies with applicable specification |
| Water Content | As per approved product specification |
| Particle Size | As per applicable specification |
Do not enter assumed numerical limits unless they are present in your actual Zotepine CoA/specification.
Depending on the product and customer requirements, Zotepine API supply may be supported with applicable technical and quality documentation, including:
Zotepine API can be supplied in packaging appropriate to the required quantity, product handling requirements and customer specifications.
Customers can contact SDP regarding:
Storage conditions should follow the applicable manufacturer's specification and stability information.
Zotepine is a dibenzothiepine-derived second-generation antipsychotic compound with activity at dopamine and serotonin receptor systems.
The CAS number of Zotepine is 26615-21-4.
The molecular formula is C₁₈H₁₈ClNOS.
The molecular weight is approximately 331.9 g/mol.
Zotepine interacts with several neurotransmitter targets, including dopamine D1 and D2 receptors and serotonin receptors such as 5-HT2A, 5-HT6 and 5-HT7.
Zotepine has been used and investigated as an antipsychotic agent, particularly in relation to schizophrenia. Its regulatory status varies by country.
Bulk availability, MOQ, pricing, documentation and lead time depend on current product availability and applicable regulatory requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |